AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.
J Med Chem. 2012 Oct 25;55(20):8827-37. doi: 10.1021/jm301119s. Epub 2012 Oct 11.
Rational structure-based design has yielded highly potent inhibitors of cathepsin K (Cat K) with excellent physical properties, selectivity profiles, and pharmacokinetics. Compounds with a 3,4-(CH₃O)₂Ph motif, such as 31, were found to have excellent metabolic stability and absorption profiles. Through metabolite identification studies, a reactive metabolite risk was identified with this motif. Subsequent structure-based design of isoteres culminated in the discovery of an optimized and balanced inhibitor (indazole, 38).
基于结构合理性的设计产生了高效的组织蛋白酶 K(Cat K)抑制剂,具有优异的物理性质、选择性和药代动力学。具有 3,4-(CH₃O)₂Ph 结构的化合物,如 31,被发现具有出色的代谢稳定性和吸收特性。通过代谢产物鉴定研究,确定了这种结构具有反应性代谢产物风险。随后基于结构的同型物设计导致发现了一种优化且平衡的抑制剂(吲唑,38)。